Skip to main content
Venus Remedies Ltd. logo

Venus Remedies Ltd. — Investor Relations & Filings

Ticker · VENUSREM ISIN · INE411B01019 LEI · 335800PBHMB6GQMFN127 BSE.NS Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2024-08-21 AGM Information
Country IN India
Listing BSE.NS VENUSREM

About Venus Remedies Ltd.

https://venusremedies.com/

Venus Remedies Ltd. is a research-driven organization specializing in the development and manufacturing of innovative pharmaceutical formulations. The company focuses on critical therapeutic segments, including antimicrobial resistance, oncology, neurology, orthopedics, and pain management. It operates advanced manufacturing facilities and maintains a dedicated research and development wing, the Venus Medicine Research Centre, which prioritizes the creation of novel drug delivery systems and solutions for multi-drug resistant infections. Its product portfolio features a diverse range of injectables and specialized treatments, such as Elores, aimed at addressing complex clinical needs. The company serves a global market, providing healthcare solutions through a commitment to scientific excellence and international regulatory standards.

Recent filings

Filing Released Lang Actions
Updates
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' for Venus Remedies Limited, detailing the agenda for the 35th AGM scheduled on 23rd September 2024. It includes ordinary and special business items such as adoption of audited standalone and consolidated financial statements for the year ended 31st March 2024, re-appointment of directors, and appointment of new independent directors. The document also references the Annual Report 2023-24 being sent electronically to members and available on the company's website and stock exchange websites. The content is primarily a notice for the AGM, outlining resolutions to be passed and procedural details for the meeting, rather than the full Annual Report or financial statements themselves. The document length is about 15,000 characters, which is consistent with a detailed AGM notice including explanatory notes and director information. Therefore, this document is best classified as AGM Information (AGM-R).
2024-08-21 English
Updates
Regulatory Filings Classification · 95% confidence The document is extremely short (215 characters) and contains only a digital signature with no substantive content or financial data. There is no indication of a report, announcement, or detailed information. It does not fit any specific report category and appears to be a regulatory or compliance-related filing with minimal content. According to the rules, such minimal content documents are best classified as Regulatory Filings (RNS).
2024-08-21 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document contains detailed unaudited consolidated financial results for the quarter ended June 30, 2024, including income, profit/loss, earnings per share, and equity share capital. It also mentions approval by the Audit Committee and Board of Directors, references SEBI (Listing Obligations and Disclosure Requirements) Regulations, and provides comparative quarterly and yearly data. The length of the document is substantial (15,000 characters), and it includes actual financial data and analysis rather than just an announcement or certification. These characteristics align with an Interim / Quarterly Report (IR) filing, which covers comprehensive financial results for a period shorter than a full fiscal year. There is no indication that this is merely an announcement or a certification, nor is it a full annual report or other filing type. Therefore, the document is best classified as an Interim / Quarterly Report (IR). Q1 2025
2024-08-16 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of financial results for the quarter ended 30.06.2024 by Venus Remedies Limited. It includes extensive financial data such as revenue, profit before and after tax, earnings per share, and consolidated and standalone figures. The presence of actual financial statements and substantive financial data for a quarterly period indicates this is a comprehensive interim financial report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or publication notice. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-08-14 English
Change in Management
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges regarding the appointment of two Independent Directors to the Board of Venus Remedies Limited. It references compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, which pertains to disclosure of material events including board appointments. The content includes detailed profiles of the appointed directors and terms of appointment. There is no financial data, earnings information, or report attached or referenced as being published. The document is clearly an announcement of changes in the company's board of directors, fitting the category of Board/Management Information (MANG). The document length (14,735 characters) supports that it is a full announcement rather than a brief notice or report publication announcement.
2024-08-13 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement dated 13 August 2024 from Venus Remedies Limited regarding the outcome of a Board Meeting. It includes approval of unaudited financial results for the quarter ended 30 June 2024 along with a limited review report by the auditors. The document contains comprehensive financial data such as revenue, expenses, profit, tax expenses, and earnings per share for the quarter, as well as notes to the financial results. The presence of detailed financial statements and auditor's limited review report indicates this is an Interim / Quarterly Report. The document also mentions appointments of additional directors and AGM details, but the primary content is the unaudited quarterly financial results with substantive financial data and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR). The document length (15,000 characters) and content confirm it is the report itself, not just an announcement or certification.
2024-08-13 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.